Accelerated approval by the US FDA in the uncommon cancer mantle cell lymphoma is just the beginning for AstraZeneca PLC's Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib), which is poised to ultimately challenge Johnson & Johnson's first-in-class megahit Imbruvica across a range of indications.
FDA approved Calquence on Oct. 31 for second-line treatment of MCL, an aggressive type of non-Hodgkin lymphoma that strikes about 3,300 in the US each year
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?